Collateral for a security interest recorded May 14, 2025 (Hercules Capital, Inc.).
Term ends Oct 16, 2032 · High confidence
20-year base term ends Nov 20, 2033
Held by Mederis Diabetes Inc.
Filed May 20, 2015 as application 14/646,246 · Granted Jun 26, 2018
Base term, 20 years from filing · capped by a resolved terminal disclaimer
Today
2013
2033
Clock starts
Nov 20, 2013
Nov 20, 2013
Term ends
Oct 16, 2032
Oct 16, 2032
Granted
Jun 26, 2018
Jun 26, 2018
base term
after the term ends
fee events
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
Capped
Terminal disclaimer
Resolved from the filed document, referencing US 10,010,617, US 10,471,127, US 11,065,304.
2 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
5
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. 2 of 3 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Nov 20, 2013, when application PCT/US2013/071067, the earliest non-provisional in its chain, was filed (this one was filed May 20, 2015) | Nov 20, 2033 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 10,010,617, US 10,471,127, US 11,065,304) | capped to Oct 16, 2032 | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Oct 16, 2032 | High confidence |
Partial family
| Application PCT/US2013/071067 | PCT application no patent term | no patent term |
| US 10,005,817 | this patent Oct 2032 | Oct 2032 |
| Application 15/986,707 | Abandoned not computed | not computed |
| Application 17/031,583 | Abandoned not computed | not computed |
| Application 19/322,608 | Pending not computed | not computed |
Partial: 1 of the 5 has no file history here, so its row comes from the patent's own record or names the application alone. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jun 24, 2015 Reel 36016, frame 858 | Nestor, John J. | Eumederis Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Jul 20, 2019 Reel 49809, frame 925 | Eumederis Pharmaceuticals Inc. | Mederis Diabetes Inc. | Assignment of Assignor's Interest |
| Feb 19, 2025 Reel 70266, frame 875 | Mederis Diabetes, LLC | Mederis Diabetes LLC | Affidavit of Address Change |
| May 14, 2025 Reel 71108, frame 692 | Altimmune, Inc.; Spitfire Pharma, LLC | Hercules Capital, Inc., as Agent | Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Oct 2032
Term ends Oct 16, 2032. Maintenance fees still fall due before then
Disclaimer cap
This term is capped by a terminal disclaimer resolved from the filed document, referencing US 10,010,617, US 10,471,127, US 11,065,304.
Citations
20
later US patents cite this one
That is top 25% of utility patents granted in 2018 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.